Fig. 2

Comparison of the cumulative incidence of the clinical events, between the ticagrelor and clopidogrel groups after inverse probability of treatment weighting. a): Secondary safety end point showing cumulative hazard over time, with A + T group (blue) demonstrating significantly higher risk compared to A + C group, b): Primary end point with no significant difference between treatment groups, c): Any revascularization events showing similar cumulative incidence between groups, d): BARC 2 bleeding events with significantly higher incidence in the A + T group compared to A + C group, e): BARC 3 or 5 bleeding events with no significant difference between groups.